Erratum: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]

Hani M. Babiker¹, Irbaz Bin Riaz², Muhammad Husnain², Mitesh J. Borad^{3

4}

Affiliations

¹ University of Arizona Cancer Center
² Department of Internal Medicine, University of Arizona, Tucson
³ Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
⁴ Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA

Published Erratum

Hani M. Babiker et al. Oncolytic Virother. 2019.

. 2019 Jan 4:8:1.

doi: 10.2147/OV.S196145. eCollection 2019.

Hani M. Babiker¹, Irbaz Bin Riaz², Muhammad Husnain², Mitesh J. Borad^{3

4}

¹ University of Arizona Cancer Center
² Department of Internal Medicine, University of Arizona, Tucson
³ Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
⁴ Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA

Abstract

[This corrects the article on p. 11 in vol. 6, PMID: 28224120.].

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
Babiker HM, Riaz IB, Husnain M, Borad MJ. Babiker HM, et al. Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072. eCollection 2017. Oncolytic Virother. 2017. PMID: 28224120 Free PMC article. Review.

1. Doniņa S, Strēle I, Proboka G, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421–426. - PMC - PubMed